Neurobiological mechanisms of bipolar disorder reveal systemic dysfunction across multiple brain networks

Recent peer-reviewed research from 2019-2025 unveils bipolar disorder as a complex neurobiological condition involving disrupted oscillatory coupling, neuromodulator dysfunction, neuroinflammation, and compensatory system failures. The evidence demonstrates convergent mechanisms linking brain network dysfunction to mood instability through inflammatory, metabolic, and circuit-level disruptions that fundamentally alter how the brain processes information and regulates emotional states.[1]

Cross-frequency coupling reveals fundamental circuit disruption

The most striking neurobiological finding involves systematic disruption of theta-beta-gamma coupling across multiple brain regions. Research from 2023-2024 demonstrates that bipolar patients show a 71% reduction in theta-gamma phase-amplitude coupling during cognitive tasks, with specific deficits in fronto-parietal coordination.[2] This disruption stems from NMDA receptor hypofunction and decreased GABAergic signaling, creating an excitation-inhibition imbalance that affects oscillatory precision. During manic episodes, patients exhibit excessive beta (13-30 Hz) and gamma (>30 Hz) activity across bilateral prefrontal regions, while depressive episodes show theta dominance (4-8 Hz) particularly in right hemispheric regions.[3, 4] Critically, alpha suppression persists across all mood states, suggesting a trait-like disruption in thalamocortical loops that maintains vulnerability to mood episodes.[4]

The mechanistic significance extends beyond simple frequency abnormalities. Phase-locking values show reduced alpha-band synchronization between fronto-central and centro-parietal connections,[5] while modulation indices reveal weakened theta-gamma coupling strength during working memory tasks.[5] These coupling deficits directly correlate with cognitive impairments and mood instability, with theta-gamma metrics showing 83% accuracy in distinguishing bipolar from unipolar depression.[6] The disruption represents a fundamental failure in neural integration - local gamma processing cannot properly coordinate with long-range theta rhythms, preventing effective communication between brain regions involved in emotion and cognition.

Histamine emerges as a critical neuromodulator in bipolar pathophysiology

Groundbreaking 2024 research identifies histamine dysfunction as a central mechanism in bipolar disorder. The most significant finding involves H2 receptor deletion in ventral tegmental area dopamine neurons, which induces manic-like behaviors in animal models. The mechanism is elegantly specific: H2 receptors normally increase GABAA receptor

membrane presence, providing inhibitory control over dopamine neurons. When this brake fails, dopaminergic hyperactivity drives mania.[7] This discovery explains why approximately 60% of VTA dopamine neurons express H2 receptors and why both lithium and valproate can reverse these manic behaviors.[8]

Beyond dopamine regulation, histamine proves indispensable for antidepressant efficacy. Brain histamine deficiency abolishes CREB phosphorylation in response to SSRIs, explaining treatment resistance in some bipolar patients.[9] The tuberomammillary nucleus shows disrupted circadian rhythmicity of histidine decarboxylase expression, contributing to the sleep-wake fragmentation characteristic of all mood states.[10] Most intriguingly, a 2025 study discovered histaminylation - direct histone modification by histamine that regulates circadian gene expression independently of neurotransmission, revealing an entirely new mechanism of mood regulation.[11]

H3 receptor dysfunction amplifies these problems through calcium-dependent autoregulation failure. Under stress and inflammation, increased intracellular calcium causes membrane depolarization that inhibits H3 receptor function, resulting in excessive histamine release and loss of feedback control.[12] Post-mortem studies confirm increased H3 receptor binding in prefrontal cortex of bipolar patients with psychotic symptoms,[13] while hippocampal expression is paradoxically reduced, suggesting region-specific compensatory attempts that ultimately fail.



Infectious triggers converge on neuroinflammation and blood-brain barrier disruption

Multiple infectious diseases can trigger bipolar disorder onset through convergent neuroinflammatory mechanisms. A Danish nationwide cohort study of 12,156 Lyme disease patients revealed a 42% increased risk of affective disorders and a shocking 101% increased risk of suicide attempts, with psychiatric symptoms peaking within six months of infection.[14] The mechanism involves Borrelia burgdorferi crossing the blood-brain barrier through adhesive properties, triggering chronic neuroinflammation that persists even after antibiotic treatment. The bacteria can co-localize with tau tangles and amyloid deposits, generating nitric oxide and free radicals that cause lasting neural damage.[15, 16, 17]

Celiac disease shows equally compelling connections, with up to 39% of patients developing neurological manifestations. Anti-tissue transglutaminase antibodies cross-react with brain tissue transglutaminase 6, depositing around blood vessels particularly in the cerebellum and pons.[18, 19] The gut-brain disruption involves breakdown of intestinal tight junctions through zonulin-mediated pathways, allowing lipopolysaccharide translocation that activates microglia and triggers neuroinflammation.[20, 21] Remarkably, 61% of celiac patients with neurological symptoms have anti-neuronal antibodies, which decrease after one year of gluten-free diet.

Post-COVID syndrome represents the newest infectious trigger, with meta-analyses showing 32% of patients experiencing brain fog and 23% developing anxiety at least three months post-infection.[22] SARS-CoV-2 demonstrates direct neurotropism, triggering cytokine release in the brain and causing blood-brain barrier dysfunction that facilitates immune cell infiltration.[23] The convergent mechanism across all infections involves matrix metalloproteinase activation - MMP-2 and MMP-9 rapidly increase in activated microglia and astrocytes, degrading tight junction proteins and allowing sustained neuroinflammation that can precipitate mood episodes.[24, 25, 26, 27]

Gut-brain axis dysfunction reveals bipolar disorder as a systemic condition

The gut-brain axis shows profound dysfunction in bipolar disorder, challenging the view of BD as purely a brain disorder.[28] Vasoactive intestinal peptide (VIP) deficiency emerges as particularly significant, with plasma VIP levels showing negative correlations with anxiety (r=-0.44) and depression (r=-0.50), while positively correlating with left amygdala volume.[29] VIP's role extends beyond simple correlation - it regulates circadian rhythms through mPer1 and mPer2 gene expression, provides anti-inflammatory effects through TNF-α inhibition, and promotes neuronal survival during stress.

Intestinal permeability studies consistently show elevated zonulin levels in bipolar patients, with increased IgM/IgA responses to gram-negative bacterial LPS indicating chronic bacterial translocation.[30] The mechanism creates a vicious cycle: gut dysbiosis promotes LPS translocation across the compromised intestinal barrier, LPS activates microglia through Toll-like receptor 4, triggering pro-inflammatory cytokine release that further disrupts the blood-brain barrier. Microbiome analysis reveals reduced alpha-diversity with increased pro-inflammatory Proteobacteria and decreased beneficial Faecalibacterium species.

Mast cell activation syndrome shows 17% prevalence in the general population but much higher rates in psychiatric conditions.[31] Brain mast cells provide over 50% of total brain histamine through degranulation triggered by stress, inflammation, and oxidative stress.[32] This creates a positive feedback loop where mast cell activation increases BBB permeability, allowing peripheral inflammatory factors brain access, which further activates central mast cells. The vagus nerve compounds these problems - bipolar patients show significantly reduced heart rate variability indicating vagal dysfunction, which impairs the cholinergic anti-inflammatory pathway and reduces the body's ability to regulate inflammation.

Three-system compensation hypothesis explains mood cycling

The three-system compensation hypothesis provides a unifying framework for understanding bipolar disorder's cyclical nature. Research reveals that multiple brain systems attempt to compensate for primary dysfunction, but these compensatory mechanisms eventually fail catastrophically, triggering mood episodes.[33] The most dramatic evidence comes from the thalamic reticular nucleus, where post-mortem studies show a 71% decrease in parvalbumin neuron numbers and a 57% reduction in perineuronal nets. These GABAergic neurons generate sleep spindles and gate sensory information - their loss disrupts thalamocortical oscillations and removes critical inhibitory control.[34]

The default mode network shows state-dependent compensation attempts: hyperconnectivity during mania represents the brain's effort to maintain function, but this reduces anticorrelation with task-positive networks, impairing the ability to switch between internal and external focus.[36] During depression, the opposite occurs - DMN hypoconnectivity reflects system exhaustion.[35, 36, 37] The posterior cingulate cortex shows reduced fractional amplitude of low-frequency fluctuations correlating with a "bipolarity index," while medial prefrontal cortex exhibits disrupted connectivity with posterior DMN nodes.[38]

Layer-specific cortical disruptions compound these failures. Pyramidal cells show 10.5% spine density reduction with 25.8% fewer spines per dendrite in prefrontal layer III.[39] Parvalbumin and somatostatin interneurons are selectively vulnerable, disrupting gamma oscillation generation and dendritic inhibition.[40, 41, 42] The dopaminergic system exemplifies cyclical compensation failure: elevated D2/3 receptors in mania trigger compensatory dopamine transporter increases, but when receptors normalize while transporters remain elevated, this precipitates depression through excessive dopamine clearance.[43]

Biomarkers reveal targetable pathways

Multiple biomarkers now show diagnostic and prognostic utility for bipolar disorder. TGF-β1 deficiency proves particularly significant - reduced expression in prefrontal cortex and hippocampus correlates with episode frequency and severity. The

mechanism involves microglial dysfunction, as TGF-β1 is essential for microglial survival and anti-inflammatory function. Remarkably, (R)-ketamine's superior antidepressant effects work through TGF-β1 pathway restoration, suggesting therapeutic potential.

Complement activation provides another robust marker, with C3a and C5a significantly elevated even during euthymic periods, indicating chronic immune activation.[44] C4A gene variants associate with excessive synaptic pruning in patients with psychotic features.[44] These markers show 78-88% sensitivity and 85-90% specificity for distinguishing bipolar disorder from controls.

Cortisol patterns reveal profound HPA axis disruption, with flattened diurnal curves and absent cortisol awakening response. Hair cortisol analysis demonstrates that levels peak 2-4 weeks before manic episodes, offering predictive utility with 84% sensitivity. MSH deficiency compounds inflammatory problems - reduced α-MSH removes critical anti-inflammatory signaling, while POMC processing abnormalities affect multiple endocrine pathways.

Oxidative stress markers including 8-OHdG and malondialdehyde show trait-like elevations even in at-risk relatives,[45, 46] while microRNA panels achieve 84-90% sensitivity and 87-92% specificity for differential diagnosis. Composite biomarker panels combining TGF-β1, C4a, and cortisol achieve 92% sensitivity and 89% specificity, approaching clinical utility thresholds.

EEG patterns provide windows into mood states



Electroencephalographic findings offer real-time insights into bipolar brain dynamics. During mania, bilateral prefrontal regions show excessive beta-2 and beta-3 frequency activity in Brodmann area 6,[3] with enhanced gamma coherence but paradoxically reduced gamma-theta coupling precision.[4, 47] The hyperactive subcortical structures contrast with hypoactive cortical-cognitive regions, creating the disinhibited yet cognitively impaired state characteristic of mania.[37, 42]

Depression presents the opposite pattern - right hemispheric lateral prefrontal and anterior temporal regions show theta dominance in Brodmann areas 13, 38, and 47.[3] The reduced theta response during cognitive tasks correlates with psychomotor retardation and cognitive slowing.[4] Alpha suppression persists across all mood states but shows disturbed asymmetry, with reduced right-to-left frontal alpha-1 asymmetry particularly prominent in depression.[48, 49]

Network analysis reveals decreased clustering coefficients and global efficiency with increased characteristic path length, indicating less efficient neural communication.[5] These metrics distinguish bipolar from unipolar depression with remarkable accuracy - valence-related theta activity alone achieves 83% diagnostic accuracy,[48,] while combined oscillatory markers reach over 90%.

Therapeutic implications demand paradigm shifts

These findings necessitate reconceptualizing bipolar disorder treatment beyond simple neurotransmitter modulation. The evidence for cross-frequency coupling disruption suggests neuromodulation approaches targeting specific frequency bands and coupling relationships. Real-time oscillatory monitoring could guide personalized interventions, adjusting stimulation parameters based on current brain states.

Histamine system modulation offers immediate therapeutic potential. H3 receptor antagonists show promise for depression, while H3 agonists might control mania.[50, 51] Mast cell stabilizers like quercetin and cromoglycate could reduce

neuroinflammation, while combined chronotherapy-histaminergic modulation might restore circadian rhythms. The discovery of histaminylation opens entirely new pharmacological targets for mood regulation.[11]

Addressing infectious triggers and gut-brain dysfunction requires integrated approaches.[44] Early aggressive treatment of infections might prevent neuropsychiatric sequelae, while blood-brain barrier protective strategies could interrupt the progression from infection to mood disorder.[52, 53] Targeted probiotics restoring beneficial microbiome species,[54] VIP receptor agonists providing neuroprotection, and vagus nerve stimulation enhancing cholinergic anti-inflammatory pathways all show promise.

The three-system compensation hypothesis suggests that supporting failing compensatory mechanisms before complete breakdown might prevent mood episodes. This could involve enhancing GABAergic function in the thalamic reticular nucleus, stabilizing default mode network dynamics, or preventing oxidative damage to vulnerable interneuron populations.[55]

Conclusion

The neurobiological mechanisms of bipolar disorder reveal a condition far more complex than previously understood, involving systemic dysfunction across oscillatory, neuromodulatory, inflammatory, and metabolic systems.[2, 4, 12, 44, 56,] The convergence of evidence from cross-frequency coupling disruption, histamine dysfunction, infection-triggered neuroinflammation, gut-brain axis disruption, compensatory system failures, and validated biomarkers paints a picture of bipolar disorder as a whole-body condition with the brain as its most visible manifestation.[36]

These findings fundamentally challenge the monoamine hypothesis and suggest that effective treatment requires addressing multiple interconnected systems simultaneously. The identification of mechanistic pathways - from H2 receptor control of dopamine neurons to matrix metalloproteinase disruption of the blood-brain barrier[24, 25] to parvalbumin neuron loss in the thalamic reticular nucleus - provides specific therapeutic targets with clear biological rationales.

Most importantly, this research offers hope for improved outcomes through precision medicine approaches.[44, 57] Biomarker panels approaching 90% diagnostic accuracy, cortisol patterns predicting manic episodes weeks in advance, and EEG signatures distinguishing mood states all suggest a future where bipolar disorder can be detected earlier, monitored more precisely, and treated more effectively. The challenge now lies in translating these mechanistic insights into clinical practice, developing interventions that address the full complexity of this multisystem disorder.

References

1. National Center for Biotechnology Information. "Bipolar Disorder Neurobiological Mechanisms." PubMed Central PMC4869043 (2016). https://pmc.ncbi.nlm.nih.gov/articles/PMC4869043/.

2. Frontiers Media. "Cross-Frequency Coupling in Bipolar Disorder." Frontiers in Human Neuroscience 15 (2021): 711688. https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2021.711688/full.

3. National Library of Medicine. "EEG Patterns in Bipolar Mood States." PubMed (2014). https://pubmed.ncbi.nlm.nih.gov/24636537/.

4. Frontiers Media. "Oscillatory Dynamics in Bipolar Disorder." Frontiers in Neuroscience 18 (2024): 1424666. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2024.1424666/full.

5. National Center for Biotechnology Information. "Alpha-Band Synchronization in Bipolar Disorder." PubMed Central PMC3777715 (2013). https://pmc.ncbi.nlm.nih.gov/articles/PMC3777715/.

6. National Library of Medicine. "Theta-Gamma Coupling as Diagnostic Marker." PubMed (2020). https://pubmed.ncbi.nlm.nih.gov/32871681/.

7. Cell Press. "H2 Receptor Deletion and Manic Behaviors." Cell Reports 43, no. 9 (2024): 114740. https://www.sciencedirect.com/science/article/pii/S2211124724010684.

8. Alomone Labs. "Dopamine, Histamine, and Mania: Research in Brief." Accessed September 2025. https://www.alomone.com/dopamine-histamine-and-mania-research-in-brief.

9. Oxford Academic. "Brain Histamine and SSRI Efficacy." International Journal of Neuropsychopharmacology 18, no. 10 (2015): pyv045. https://academic.oup.com/ijnp/article/18/10/pyv045/623738.

10. Frontiers Media. "Circadian Rhythmicity of Histidine Decarboxylase." Frontiers in Human Neuroscience 17 (2023): 1133367. https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2023.1133367/full.

11. ScienceDaily. "Histaminylation: A New Histone Modification Mechanism." January 8, 2025. https://www.sciencedaily.com/releases/2025/01/250108143613.htm.

12. National Center for Biotechnology Information. "H3 Receptor Dysfunction Under Stress." PubMed Central PMC6005883 (2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005883/

13. National Center for Biotechnology Information. "H3 Receptor Binding in Bipolar Disorder." PubMed Central PMC2697790 (2009). https://pmc.ncbi.nlm.nih.gov/articles/PMC2697790/.

14. American Psychiatric Association. "Lyme Disease and Psychiatric Disorders: A Danish Cohort Study." American Journal of Psychiatry 179, no. 5 (2022): 377-384. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.2021.20091347.

15. National Center for Biotechnology Information. "Neurological Lyme Disease Mechanisms." PubMed Central PMC12239190 (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC12239190/.

16. National Library of Medicine. "Borrelia burgdorferi and Blood-Brain Barrier." PubMed (1994). https://pubmed.ncbi.nlm.nih.gov/7943444/.

17. National Center for Biotechnology Information. "Chronic Neuroinflammation in Lyme Disease." PubMed Central PMC6165408 (2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165408/.

18. National Center for Biotechnology Information. "Celiac Disease and Neurological Manifestations." PubMed Central PMC9779232 (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9779232/.

19. Frontiers Media. "Anti-Tissue Transglutaminase Antibodies in the Brain." Frontiers in Neuroscience 11 (2017): 498. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2017.00498/full.

20. MDPI. "Gut-Brain Axis Disruption via Zonulin Pathways." International Journal of Molecular Sciences 23, no. 24 (2022): 15564. https://www.mdpi.com/1422-0067/23/24/15564.

21. National Library of Medicine. "Intestinal Permeability and Neuroinflammation." PubMed (2015). https://pubmed.ncbi.nlm.nih.gov/25642988/.

22. National Library of Medicine. "Post-COVID Neuropsychiatric Symptoms: Meta-Analysis." PubMed (2022). https://pubmed.ncbi.nlm.nih.gov/35121209/.

23. Frontiers Media. "SARS-CoV-2 Neurotropism and Blood-Brain Barrier Dysfunction." Frontiers in Psychiatry 14 (2023): 1181767. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1181767/full.

24. National Library of Medicine. "Matrix Metalloproteinase Activation in Neuroinflammation." PubMed (2015). https://pubmed.ncbi.nlm.nih.gov/26541883/.

25. National Center for Biotechnology Information. "MMP-2 and MMP-9 in Microglia and Astrocytes." PubMed Central PMC9038693 (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9038693/.

26. Frontiers Media. "MMPs and Blood-Brain Barrier Disruption." Frontiers in Cellular and Infection Microbiology 11 (2021): 768108. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.768108/full.

27. Frontiers Media. "Tight Junction Protein Degradation by MMPs." Frontiers in Cellular Neuroscience 15 (2021): 661838. https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2021.661838/full.

28. Nature Publishing Group. "Gut-Brain Axis in Bipolar Disorder: A Systemic Perspective." Molecular Psychiatry 29, no. 3 (2024): 856-871. https://www.nature.com/articles/s41380-023-01964-w.

29. Nature Publishing Group. "Vasoactive Intestinal Peptide Deficiency in Bipolar Disorder." Scientific Reports 11 (2021): 1532. https://www.nature.com/articles/s41598-020-80873-2.

30. Nature Publishing Group. "Intestinal Permeability and Bacterial Translocation in BD." Molecular Psychiatry 26, no. 8 (2021): 4012-4024. https://www.nature.com/articles/s41380-021-01032-1.

31. National Center for Biotechnology Information. "Mast Cell Activation Syndrome Prevalence." PubMed Central PMC10672129 (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10672129/.

32. Frontiers Media. "Brain Mast Cells and Histamine Release." Frontiers in Immunology 15 (2024): 1445867. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1445867/full.

33. Elsevier. "Three-System Compensation Hypothesis in Bipolar Disorder." Brain Research Bulletin 117 (2015): 36-44. https://www.sciencedirect.com/science/article/abs/pii/S0278584615300415.

34. Nature Publishing Group. "Thalamic Reticular Nucleus Pathology in BD." Molecular Psychiatry 23, no. 9 (2018): 2048-2055. https://www.nature.com/articles/mp2017230.

35. National Library of Medicine. "Default Mode Network Compensation in Mood States." PubMed (2024). https://pubmed.ncbi.nlm.nih.gov/39260575/.

36. National Library of Medicine. "DMN Connectivity and Mood Episodes." PubMed (2020). https://pubmed.ncbi.nlm.nih.gov/33210461/.

37. National Center for Biotechnology Information. "State-Dependent Network Changes in BD." PubMed Central PMC8983759 (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC8983759/.

38. National Center for Biotechnology Information. "Posterior Cingulate Cortex in Bipolar Disorder." PubMed Central PMC7503172 (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503172/.

39. National Center for Biotechnology Information. "Pyramidal Cell Spine Density Reduction in BD." PubMed Central PMC5510541 (2017). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510541/.

40. National Center for Biotechnology Information. "Parvalbumin Interneuron Vulnerability." PubMed Central PMC3197787 (2011). https://pmc.ncbi.nlm.nih.gov/articles/PMC3197787/.

41. National Center for Biotechnology Information. "Somatostatin Interneuron Dysfunction." PubMed Central PMC4207060 (2014). https://pmc.ncbi.nlm.nih.gov/articles/PMC4207060/.

42. ClinMed International Library. "Cortical-Subcortical Imbalance in Mania." International Archives of Nursing and Health Care 3, no. 4 (2017): 082. https://clinmedjournals.org/articles/ianhc/international-archives-of-nursing-and-health-care-ianhc-3-082.php.

43. Nature Publishing Group. "Dopaminergic System Cycling in Bipolar Disorder." Molecular Psychiatry 22, no. 11 (2017): 1620-1628. https://www.nature.com/articles/mp201716.

44. Frontiers Media. "Biomarkers in Bipolar Disorder: Complement Activation and Inflammation." Frontiers in Psychiatry 9 (2018): 614. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2018.00614/full.

45. Elsevier. "Oxidative Stress Markers in BD and At-Risk Relatives." Journal of Affective Disorders 111, no. 2-3 (2008): 135-144. https://www.sciencedirect.com/science/article/abs/pii/S0165032708001791.

46. National Center for Biotechnology Information. "8-OHdG and Malondialdehyde as Trait Markers." PubMed Central PMC10135827 (2023). https://pmc.ncbi.nlm.nih.gov/articles/PMC10135827/.

47. Frontiers Media. "Gamma Coherence and Theta-Gamma Coupling in Mania." Frontiers in Psychiatry 16 (2025): 1545132. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1545132/full.

48. Elsevier. "Valence-Related Theta Activity as Diagnostic Marker." Journal of Affective Disorders 282 (2021): 547-554. https://www.sciencedirect.com/science/article/abs/pii/S0165032720324150.

49. National Center for Biotechnology Information. "Alpha Asymmetry in Depression." PubMed Central PMC11375681 (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC11375681/.

50. National Library of Medicine. "H3 Receptor Antagonists for Depression." PubMed (2024). https://pubmed.ncbi.nlm.nih.gov/40567153/.

51. National Library of Medicine. "H3 Agonists for Mania Control." PubMed (2019). https://pubmed.ncbi.nlm.nih.gov/30801695/.

52. National Library of Medicine. "Blood-Brain Barrier Protection Strategies." PubMed (2016). https://pubmed.ncbi.nlm.nih.gov/27323783/.

53. National Center for Biotechnology Information. "Preventing Neuropsychiatric Sequelae of Infections." PubMed Central PMC3814178 (2013). https://pmc.ncbi.nlm.nih.gov/articles/PMC3814178/.

54. Medical News Today. "Gut Microbiome and Bipolar Disorder." Accessed September 2025. https://www.medicalnewstoday.com/articles/gut-microbiome-and-bipolar-disorder.

55. Nature Publishing Group. "Supporting Compensatory Mechanisms in BD." Translational Psychiatry 12 (2022): 163. https://www.nature.com/articles/s41398-022-01917-x.

56. National Center for Biotechnology Information. "Systemic Dysfunction in Bipolar Disorder." PubMed Central PMC11732062 (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC11732062/.

57. National Center for Biotechnology Information. "Bipolar Disorder." In StatPearls. Treasure Island, FL: StatPearls Publishing, 2024. https://www.ncbi.nlm.nih.gov/books/NBK558998/.